BACKGROUND: 123I-labelled 2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) imaging is a diagnostic tool to help differentiate dementia with Lewy bodies (DLB) from Alzheimer's disease (AD). However, in animals, cholinesterase inhibitors (ChEi) have been reported to reduce radioligand binding to the striatal dopamine transporter. As ChEi are frequently used in people with dementia, it is important to determine whether their use affects 123I-FP-CIT uptake in the striatum. OBJECTIVE: To clarify whether chronic ChEi therapy modulates striatal dopamine transporter binding measured by 123I-FP-CIT in patients with AD, DLB and Parkinson's disease with dementia (PDD). DESIGN: Cross sectional study in 99 patients with AD (nine on ChEi, 25 not on ChEi), DLB (nine on ChEi, 19 not on ChEi) and PDD (six on ChEi, 31 not on ChEi) comparing 123I-FP-CIT striatal binding (caudate, anterior and posterior putamen) in patients receiving compared with those not receiving ChEi, correcting for key clinical variables including diagnosis, age, sex, Mini-Mental State Examination score, severity of parkinsonism and concurrent antidepressant use. RESULTS: As previously described, 123I-FP-CIT striatal uptake was lower in DLB and PDD subjects compared with those with AD. Median duration of ChEi use was 180 days. 123I-FP-CIT uptake was not significantly reduced in subjects receiving ChEi compared those not receiving ChEi (mean percentage reduction: AD 4.3%; DLB 0.7%; PDD 6.1%; p = 0.40). ChEi use did not differentially affect striatal 123FP-CIT uptake between patient groups (p = 0.83). CONCLUSIONS: Use of ChEi does not significantly influence the ability of 123I-FP-CIT imaging to distinguish AD from DLB.
BACKGROUND: 123I-labelled 2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) imaging is a diagnostic tool to help differentiate dementia with Lewy bodies (DLB) from Alzheimer's disease (AD). However, in animals, cholinesterase inhibitors (ChEi) have been reported to reduce radioligand binding to the striatal dopamine transporter. As ChEi are frequently used in people with dementia, it is important to determine whether their use affects 123I-FP-CIT uptake in the striatum. OBJECTIVE: To clarify whether chronic ChEi therapy modulates striatal dopamine transporter binding measured by 123I-FP-CIT in patients with AD, DLB and Parkinson's disease with dementia (PDD). DESIGN: Cross sectional study in 99 patients with AD (nine on ChEi, 25 not on ChEi), DLB (nine on ChEi, 19 not on ChEi) and PDD (six on ChEi, 31 not on ChEi) comparing 123I-FP-CIT striatal binding (caudate, anterior and posterior putamen) in patients receiving compared with those not receiving ChEi, correcting for key clinical variables including diagnosis, age, sex, Mini-Mental State Examination score, severity of parkinsonism and concurrent antidepressant use. RESULTS: As previously described, 123I-FP-CIT striatal uptake was lower in DLB and PDD subjects compared with those with AD. Median duration of ChEi use was 180 days. 123I-FP-CIT uptake was not significantly reduced in subjects receiving ChEi compared those not receiving ChEi (mean percentage reduction: AD 4.3%; DLB 0.7%; PDD 6.1%; p = 0.40). ChEi use did not differentially affect striatal 123FP-CIT uptake between patient groups (p = 0.83). CONCLUSIONS: Use of ChEi does not significantly influence the ability of 123I-FP-CIT imaging to distinguish AD from DLB.
Authors: M A Piggott; E F Marshall; N Thomas; S Lloyd; J A Court; E Jaros; D Burn; M Johnson; R H Perry; I G McKeith; C Ballard; E K Perry Journal: Brain Date: 1999-08 Impact factor: 13.501
Authors: Maartje M L de Win; Jan B A Habraken; Liesbeth Reneman; Wim van den Brink; Gerard J den Heeten; Jan Booij Journal: Neuropsychopharmacology Date: 2005-05 Impact factor: 7.853
Authors: Z Walker; D C Costa; R W H Walker; K Shaw; S Gacinovic; T Stevens; G Livingston; P Ince; I G McKeith; C L E Katona Journal: J Neurol Neurosurg Psychiatry Date: 2002-08 Impact factor: 10.154
Authors: M Laruelle; R M Baldwin; R T Malison; Y Zea-Ponce; S S Zoghbi; M S al-Tikriti; E H Sybirska; R C Zimmermann; G Wisniewski; J L Neumeyer Journal: Synapse Date: 1993-04 Impact factor: 2.562
Authors: Shupeng Li; Kun Yang Kim; Jong Hun Kim; Jin Hoi Kim; Moon Seok Park; Jong Yoon Bahk; Myeong Ok Kim Journal: Neurosci Lett Date: 2004-06-03 Impact factor: 3.046
Authors: Marta Marquie; Joseph J Locascio; Dorene M Rentz; J Alex Becker; Trey Hedden; Keith A Johnson; John H Growdon; Stephen N Gomperts Journal: Alzheimers Res Ther Date: 2014-08-27 Impact factor: 6.982
Authors: J J van der Zande; J Booij; P Scheltens; P G H M Raijmakers; A W Lemstra Journal: Eur J Nucl Med Mol Imaging Date: 2016-01-30 Impact factor: 9.236